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ABSTRACT
Hematopoietic cell transplantation is the only curative therapy for patients with myelodysplastic syndrome
(MDS). However, treatment-related toxicity and, in patients with advanced MDS (refractory anemia with
excess blasts [RAEB]; RAEB in transformation [RAEB-T]) or transformation to acute myeloid leukemia with
multilineage dysplasia (tAML), posttransplantation relapse continue to be prevalent. Induction chemotherapy
(IC) has been used in an attempt to decrease the risk of posttransplantation relapse, but the benefit for
posttransplantation long-term survival is uncertain. We reviewed results in 125 patients with advanced MDS
and tAML who received transplants from HLA-identical related or unrelated donors after preparation with
myeloablative conditioning regimens. Thirty-three patients (3 with RAEB, 6 with RAEB-T, and 24 with tAML)
received IC before transplantation, and 92 patients (62 with RAEB, 22 with RAEB-T, and 8 with tAML) did
not. Seventy-six patients were conditioned with oral busulfan 16 mg/kg, which was adjusted to achieve
steady-state plasma concentrations of 800 to 900 ng/mL, plus cyclophosphamide 2 60 mg/kg, and 49 patients
received busulfan 7 mg/kg (without dose adjustment) and total body irradiation 6  200 cGy given over 3 days.
There was no evidence of a benefit in posttransplantation outcome associated with prior IC, either for patients
with RAEB/RAEB-T or those with tAML, with either conditioning regimen. There was a correlation of the
severity of pretransplantation flow cytometric aberrancies on marrow cells and posttransplantation relapse.
Further studies that randomize patients to IC versus no IC need to appropriately address the possible
beneficial effect of IC.
© 2005 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
The only currently available therapy with curative
otential for patients with myelodysplastic syndrome
MDS) is hematopoietic cell transplantation (HCT)
1]. In patients with low myeloblast counts in the
arrow (5%) and peripheral blood (1%)—ie,
hose with refractory anemia or refractory cytopenia
ith multilineage dysplasia, with or without ring sid-
roblasts, as characterized by the French-American-
ritish (FAB) or World Health Organization classiﬁ-
ation [2-4]—transplantation results are excellent. As t
B&MThe marrow blast count increases or MDS transforms
nto acute myeloid leukemia (AML; by FAB or World
ealth Organization criteria), the success rates with
llogeneic HCT progressively decline [5,6]. The same
s true with increasing risk scores as determined by the
nternational Prognostic Scoring System (IPSS) [7].
he major reason for lower success rates in patients
ith more advanced disease is the higher incidence of
osttransplantation relapse [8].
In an effort to decrease the risk of posttransplan-
ation relapse, pretransplantation induction chemo-
herapy (IC) has been used to reduce the disease bur-
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6en, speciﬁcally, the proportion of marrow blasts [9].
owever, IC is associated with toxicity. Patients with
DS tend to have slow hematopoietic recovery, and
n some studies mortality has been as high as 15%
10]. In addition, pretransplantation therapy may con-
ribute to posttransplantation (nonrelapse) toxicity
nd mortality. Such an effect may negate any beneﬁt
chieved with regard to lower relapse rates. No con-
rolled study has investigated the potential beneﬁt of
C for posttransplantation relapse-free survival (RFS)
n patients with advanced MDS. We performed a
etrospective analysis in patients with advanced MDS
ho underwent transplantation at the Fred Hutchin-
able 1. Patient and Disease Characteristics
Characteristic
Induction
Chemotherapy
Yes No
o. of patients 33 92
ge (y), range (median) 2–64 (45) 3–66 (50)
ender, M/F 17/16 59/33
tiology
De novo 28 60
Secondary 5 32
isease duration (mo), range (median) 1–43 (6) 1–62 (6)
AB stage
RAEB 3 62
RAEB-T 6 22
tAML 24 8
PSS risk group
Low 0 1
Intermediate-1 10 20
Intermediate-2 8 37
High 15 33
Not scored* 0 1†
MV serology
Positive 20 49
Negative 13 43
VHD prophylaxis
MTX/CSP 27 69
MTX/FK506 0 6
MTX/CSP FK506 1 5
MTX/CSP HAT 0 2
MTX/CSP rapamycin 0 4
CSP/MMF 4 5
T-cell depletion 1 0
None† 0 1
onor
HLA-identical sibling 16 46
Alternative related donor‡ 0 3
HLA-identical unrelated 17 43
ource of stem cells
Peripheral blood 18 27
Bone marrow 15 65
onditioning regimen
tBuCy 21 55
BuTBI 12 37
AT indicates humanized anti-Tac; MTX, methotrexate; CSP,
cyclosporine; MMF, mycophenolate mofetil.
Cytogenetic data were unavailable.
Syngeneic donor.
HLA-identical family member other than a sibling.on Cancer Research Center from 1992 to 2002 and †
6ompared outcomes in patients who did receive IC
nd those who did not.
ATERIALS AND METHODS
atients
From December 1992 to October 2002, 125 patients
ith advanced MDS or patients who had developed
ML (tAML) received HCT from HLA-identical re-
ated or unrelated donors. Patient and disease character-
stics are summarized in Table 1. Most patients had de
ovo MDS. The breakdown between FAB categories
iffered signiﬁcantly between patients who did and those
ho did not receive IC. Patients who received IC were
ore likely to have a diagnosis of tAML (73%), whereas
atients who did not receive IC were more likely to have
diagnosis of refractory anemia with excess blasts
RAEB; 67%). However, there were no signiﬁcant dif-
erences regarding IPSS classiﬁcation or cytogenetic
isk. In 1 patient, the karyotype was unknown, and the
PSS score could not be calculated. The IPSS was ap-
lied to all patients with MDS, regardless of etiology.
here was no signiﬁcant difference between groups with
egard to recipient cytomegalovirus (CMV) serology or
onor type. Patients who received IC were more likely
o have received granulocyte colony-stimulating factor–
obilized peripheral blood stem cells, whereas patients
ho did not receive IC were more likely to have received
one marrow as a source of stem cells.
nduction Chemotherapy
Thirty-three patients received IC 1 to 6 months
median, 2 months) before transplantation. Most pa-
ients received cytarabine for 7 days and an anthracy-
line for 3 days. The FAB classiﬁcations used for the
urpose of this study were determined from bone
arrow examinations performed before the adminis-
ration of IC. Other regimens used are listed in Table
. Some patients had also received hydroxyurea, ste-
oids, antithymocyte globulin, or thalidomide at var-
ous time intervals before transplantation.
ransplantation Conditioning Regimens
Forty-nine patients were conditioned with busul-
an (Bu) and total body irradiation (TBI) (BuTBI)
able 2. Type of Induction Chemotherapy
Induction Regimen No. Patients %
nthracycline/cytarabine 20 61
opotecan/cytarabine 7 21
CTER* 4 12
LAG† 1 3
igh-dose cytarabine 1 3
Dexamethasone, cytarabine, thioguanine, etoposide, and daunorubicin.
Fludarabine, cytarabine, and granulocyte colony-stimulating factor.
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Chemotherapy and Posttransplantation Relapse in MDS
B11]. This regimen consisted of Bu 0.44 mg/kg orally
very 6 hours for 16 doses on days 7 to 4, for a
otal of 7 mg/kg (steady-state plasma levels of Bu were
31 to 247 ng/mL; median, 437 ng/mL; no dose
djustments were made), and TBI delivered in 200-
Gy fractions (exposure rate, 6-7 cGy/min) from 2
pposing cobalt 60 sources twice daily at least 6 hours
part on days 3 to 1 (total dose, 1200 cGy).
Seventy-six patients were conditioned with tBuCy
8]. This regimen consisted of Bu orally every 6 hours
or a total of 16 doses. The starting dose was 1 mg/kg.
lasma samples for pharmacokinetic studies were col-
ected at 0, 1, 2, 4, and 6 hours after the morning doses
n days 1, 2, and 3 of Bu administration [12-14]. Dose
djustments were made for subsequent doses to main-
ain-steady state plasma concentrations of Bu 800 to
00 ng/mL. Thirty-seven patients achieved that target
ange with the prescribed dose, 15 required increases,
nd 20 required decreases in Bu doses. Levels were
navailable in 6 patients. The median steady-state
evel among 72 patients was 867 ng/mL (the Bu
teady-state level reported is the mean of the values
bserved in each patient on days 1, 2, and 3). All
atients received seizure prophylaxis with phenytoin
s previously described [8,15]. Cy was given intrave-
ously at 60 mg/kg daily for 2 consecutive days after
he last dose of Bu.
ource of Hematopoietic Stem Cells
Sixty-ﬁve patients received HCT from family
embers: 61 from HLA-identical siblings, 1 from a
yngeneic twin, and 3 from phenotypically identical
amily members other than siblings, as determined by
igh-resolution HLA typing. Sixty patients received
CT from unrelated HLA-matched donors [16].
mong patients who received IC, the source of stem
ells was bone marrow in 15 and peripheral blood in
8. Among patients who did not receive IC, the source
f stem cells was bone marrow in 65 and peripheral
lood in 27. Stem cells were infused within 24 hours
f completion of TBI or within 36 to 48 hours of the
ast dose of Cy.
raft-versus-Host Disease Prophylaxis
For 96 patients, graft-versus-host disease
GVHD) prophylaxis consisted of intravenous meth-
trexate and cyclosporine, as previously described
17]. GVHD prophylaxis for the remaining 29 pa-
ients is summarized in Table 1. Therapy for the
reatment of acute GVHD consisted of methylpred-
isolone 1 or 2 mg/kg/d, depending on the clinical
anifestations. Steroid-refractory GVHD was treated
ith a variety of methods, including monoclonal an-
ibodies, sirolimus, antithymocyte globulin, or myco-
henolate mofetil [18,19]. GVHD was diagnosed and
raded according to consensus criteria [20]. t
B&MTlow Cytometric Scoring
Flow cytometric scoring was performed on the
ost-IC pretransplantation marrow samples in 29 of
3 patients who had received IC. Pretransplantation
ow scores were available on 65 of 92 patients who did
ot receive IC. The ﬂow scores were developed as a
eans to quantify and standardize complex ﬂow cyto-
etric aberrancies observed in patients with MDS.
he score considers immunophenotypic aberrancies
f myeloid and monocytoid cells, as well as the pro-
ortion of blasts in the marrow samples. A previous
tudy indicated that pretransplantation ﬂow scores of
arrow cells correlated with IPSS scores and that
ncreasing ﬂow scores were associated with an increas-
ng probability of posttransplantation relapse [21].
efinition of End Points
Engraftment and rejection. The day of engraftment
as deﬁned as the ﬁrst of 3 days on which the absolute
eutrophil count remained greater than 0.5  109/L
22]. Evidence of graft rejection was sought in patients
ho did not reach 0.5  109 neutrophils per liter by
ay 28, in patients who survived past day 28 without
eutrophil recovery, and in patients with a decline in
ounts after an initial recovery. When donor and host
ere different sexes, ﬂuorescent in situ hybridization
ith X- and Y-chromosome probes were used to de-
ermine the donor versus host origin of bone marrow
ononuclear cells [23]. When donor and host were
he same sex, DNA from marrow samples was ampli-
ed from several variable number tandem repeat loci
o determine donor versus host origin [24].
Relapse. All patients had bone marrow evaluations
erformed on days 28 and 84 after transplantation for
ytogenetic, ﬂow cytometric, and histopathologic
nalysis. The same analyses were performed annually
nd as clinically indicated. Relapse was deﬁned as the
resence of dysplastic cells identiﬁed by ﬂow cytom-
try, morphologic evidence of dysplastic blasts, or the
resence of cytogenetic abnormalities identiﬁed be-
ore transplantation [25]. In patients with morpho-
ogic, hematologic, or cytogenetic evidence of relapse,
elapse (rather than rejection) was considered to be
he cause of failed engraftment.
Infection. All patients received prophylactic ex-
ended-spectrum antibiotics when the neutrophil
ount was less than 500/L. From day 20 until day
60 after transplantation, blood samples were ob-
ained weekly in all patients for pp65 CMV antigen
etermination. Interstitial pneumonia was diagnosed
y culture or Gram stain of sputum or bronchoalveo-
ar lavage ﬂuid, by open lung biopsy, or at autopsy.
reemptive therapy with acyclovir, ﬂuconazole, and
o-trimoxazole, as previously described, was used in
ll patients who tolerated such medications [26]. Pa-
ients who did not tolerate co-trimoxazole received
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6apsone. All CMV-seronegative patients received
creened or leukoreduced blood products. Ganciclovir
as given preemptively and was continued for at least
weeks in any patient who developed CMV pp65
ntigenemia [27,28]. Foscarnet was used in patients
ho were intolerant of ganciclovir and in those be-
ieved to show ganciclovir resistance [29].
Causes of death. In patients with evidence of re-
apse, relapse was considered the primary cause of
eath regardless of other associated events. In patients
ith severe GVHD requiring immunosuppressive
herapy who subsequently developed fatal infections,
he cause of death was listed as GVHD plus infection.
atal infections other than interstitial pneumonias
hat occurred in the absence of immunosuppressive
herapy for GVHD or relapse were listed as the cause
f death. For the purpose of this study, interstitial
neumonia was classiﬁed as an entity separate from
nfection for determining the cause of death. Multi-
rgan failure was considered the cause of death when
t occurred in the absence of relapse and was believed
ot to be primarily due to preceding GVHD or in-
ection.
tatistical Analysis
Overall survival and RFS were estimated by using
he Kaplan-Meier method [30]. Cumulative incidence
urves for relapse, nonrelapse mortality (NRM), and
VHD were estimated according to methods previ-
usly described. Because there was no event leading to
ensoring before the last occurrence of acute GVHD,
2 analysis was used to compare the incidence of acute
VHD. Results were analyzed as of November 30,
003. Given the uneven distribution of patients by
AB criteria, a subgroup analysis was performed on
atients with a diagnosis of RAEB/RAEB in transfor-
ation (RAEB-T) or tAML.
ESULTS
esponse to IC
Among 33 patients who received IC, 11 had no
able 3. Incidence of Acute GVHD*
Variable IC†/No IC
G
IC
ll patients 31†/89*‡§ 81%
elated 14/48 62%
nrelated 17/41 94%
One patient died before day 28 without evidence of GVHD.
Two patients died before day 28 without evidence of GVHD.
One patient had a syngeneic transplantation.
One patient died of graft failure.esponse, and 18 achieved complete remissions. ‡
8mong the 18, 4 patients achieved complete remis-
ions as determined by marrow morphology but did
ot recover normal red blood cell (n  2), platelet (n
1), or granulocyte (n  1) counts. Five relapsed
efore transplantation.
ngraftment
Thirty-one patients who received IC showed neu-
rophil engraftment or developed GVHD (considered
vidence of donor cell engraftment) by day 28, and 2
atients died before day 28 and were not evaluable for
ngraftment. Among 92 patients who did not receive
C, 90 showed engraftment or developed GVHD by
ay 28. One patient died before day 28 without evi-
ence of engraftment or GVHD. One patient died
econdary to graft failure.
raft-versus-Host Disease
Among 31 evaluable patients who received IC, 25
81%) developed grade II to IV acute GVHD, and 13
42%) developed grade III to IV acute GVHD.
mong 89 evaluable patients (excluding 1 patient with
syngeneic transplant) who did not receive IC, 73
82%) developed grade II to IV GVHD, and 35 (39%)
eveloped grade III to IV GVHD (Table 3). Chronic
VHD occurred in 43% of patients who received IC
nd in 48% of patients who did not receive IC. There
as no statistically signiﬁcant correlation between the
able 4. Incidence of GVHD and Relapse
IC
Grade of Acute GVHD
0 I II III IV
es
Relapse* 1 2 5 4 1
No relapse† 3 0 7 2 6
o
Relapse‡ 3 1 12 5 4
No relapse* 9 3 26 20 6
Two patients died before day 28 without evidence of GVHD.
Two patients died before day 28 without evidence of GVHD.
Acute GVHD*
I-IV GVHD Grade III-IV GVHD
No IC IC No IC
82% 42% 39%
83% 23% 33%
78% 53% 44%rade IOne relapsed patient had a syngeneic transplantation.
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Btage of GVHD and the subsequent probability of
elapse in either group (Table 4).
elapse
Among 33 patients who received pretransplanta-
ion IC (13 of whom were in remission at the time of
ransplantation), 14 relapsed at 1 to 30 months (me-
ian, 3 months) after transplantation. The cumulative
ncidence of relapse at 3 years was 53% (81% for
elated and 31% for unrelated transplant recipients).
ne patient with relapse responded to donor lympho-
yte infusion (DLI) and is alive more than 6 years after
LI. Another patient with relapse was treated with
LI followed by a nonmyeloablative transplantation
nd died secondary to acute GVHD. The remaining
2 patients died with relapsed disease after receiving
hemotherapy (n  4) or after withdrawal of immu-
osuppression in an attempt to induce a graft-versus-
DS reaction (n  8).
Among 92 patients who did not receive IC, 26
elapsed 1 to 47 months (median, 3 months) after
ransplantation. The cumulative incidence of relapse
t 3 years was 31% (41% for related and 19% for
nrelated transplants). Three patients with relapse are
live; 1 was successfully treated with DLI, another was
reated with withdrawal of immunosuppression, and
he third received a second transplant. Of the 23
atients who died from relapse, 13 were “treated” by
ithdrawal of immunosuppression; 2 received gemtu-
umab ozogamicin ; 4 received other chemotherapy; 1
eceived DLI; 1 received chemotherapy followed by
LI; and 2 received no treatment. The 1 patient who
eceived DLI remains alive in remission.
able 5. Outcomes after Induction Chemotherapy
Cause of Death
(No. of Patients)
Disease State Before
Transplantation
CR CR-Relapsed* NR
ll patients (33) 17 5 11
Relapse 5 2 7
MOF 1 2 2
GVHD 1 1 1
Infection 2 0 0
uTBI conditioned (12) 7 1 4
Relapse 2 0 2
MOF 0 1 2
GVHD 1 0 0
Infection 1 0 0
BuCy conditioned (21) 10 4 7
Relapse 3 2 5
MOF 1 1 0
GVHD 0 1 1
Infection 1 0 0
R indicates complete response; NR, no response; MOF, multior-
gan failure; GVHD, graft-versus-host disease.
Patients who achieved a CR with induction chemotherapy but
relapsed before transplantation.Relapse as a cause of death among patients who ‡
B&MTeceived IC was dependent on the lack of response to
C. Overall, 22 (67%) of 33 patients given IC achieved
emissions, and 7 (21%) died from posttransplantation
elapse, compared with 7 (64%) of 11 patients who did
ot respond to IC (Table 5).
ffect of Flow Cytometric Scores
Results of the ﬂow score analysis performed on 29
atients who received IC before transplantation and
5 patients who did not are summarized in Table 6. In
ll patients, regardless of IC, high ﬂow scores were
redictive of high relapse rates after transplantation.
his signiﬁcantly affected overall survival in patients
ho did not receive IC (P  .05), and a trend was
bserved among patients who received IC (P  .16;
igure 1). Flow score changes among the 5 patients
ho had ﬂow scores determined before and again after
C before transplantation were inconsistent and did
ot correlate with responses to IC.
onrelapse Mortality
Causes of death are summarized in Table 7.
mong the 92 patients who did not receive IC, 36 died
rom transplant-related complications, for a 3-year
umulative incidence of 44% (28% for related and
2% for unrelated transplants), compared with 10 of
3 patients who did receive IC, for a cumulative inci-
ence at 3 years of 34% (19% for related and 44% for
nrelated transplants). The major cause of NRM for
atients who received IC was GVHD, whereas the
ajor cause of NRM for patients who did not receive
C was infection. Four (12%) of 33 patients given IC
ied secondary to multiorgan failure, compared with 5
5%) of 92 patients who did not receive IC. Overall,
he difference in NRM was not signiﬁcant between
atients who received IC and patients who did not
Figure 2A). Nor did the use of IC signiﬁcantly affect
RM when considering the subgroups of patients
ith either tAML or RAEB/RAEB-T separately (Fig-
re 2B and C).
able 6. Posttransplantation Outcome by Pretransplantation Flow
cores
Flow Score
Total
(n) Relapse NRM* Alive
C†
Normal/mild/moderate
(0–3) 12 50% 30% 40%
Severe (4–9) 15 57% 43% 15%
o IC‡
Normal/mild/moderate
(0–3) 13 28% 25% 47%
Severe (4–9) 52 40% 44% 16%
Nonrelapse mortality.
Induction chemotherapy given before transplantation.
No pretransplantation induction chemotherapy given.
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7elapse-Free Survival
Overall, RFS did not differ signiﬁcantly between
atients who had received IC (13% at 3 years) and
hose who had not (26% at 3 years) (P  .26; Figure
A). There was no signiﬁcant difference in RFS be-
ween related and unrelated transplant recipients.
Among 33 patients given IC, 24 had progressed to
AML before the start of IC, compared with 8 of 92
igure 1. Overall survival (OS) by ﬂow score severity. A, OS
ccording to the severity of ﬂow score in patients who did not
eceive IC. B, OS according to the severity of ﬂow score in patients
ho did receive IC. (Flow indicates ﬂow score; 0-3, low or moder-
te; 4-9, severe).
able 7. Causes of Death
Cause of Death
No. Patients
IC No IC
otal 23 59
elapse 12* 23†
rgan failure  infection  GVHD 4 6
VHD  infection 5 8
nfection 2 20
entral nervous system hemorrhage 0 1
raft failure 0‡ 1§
One patient who relapsed after transplantation is alive in remission.
Three patients who relapsed after transplantation are alive in remis-
sion.
Two patients died before establishing engraftment.wOne patient died before established engraftment
0atients who did not receive IC. RFS at 3 years was
% for patients with tAML who had received IC and
% for patients who had not (P .9). It is noteworthy,
owever, that all patients with tAML who had not
eceived IC subsequently died of relapse (Figure 3B).
he difference in RFS after transplantation between
atients with tAML who had received IC and were
ubsequently conditioned with BuTBI (17% at 3
ears) and those conditioned with tBuCy (0% at 3
ears) was not signiﬁcant (P  .67).
Three-year RFS among 9 patients with RAEB/
AEB-T given IC was 26%, compared with 29%
mong 84 patients who did not receive IC (Figure
igure 2. Nonrelapse mortality (NRM). A, NRM according to
eceipt of IC versus no IC. B, NRM for patients with tAML. C,
RM for patients with RAEB/RAEB-T. The FAB classiﬁcation
as determined before the administration of IC.
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BC). There was no signiﬁcant difference in RFS
mong patients with RAEB/RAEB-T who had re-
eived IC and were conditioned with tBuCy (67% at 3
ears) or BuTBI (25% at 3 years) (P  .93), although
he numbers were small.
ISCUSSION
Treatment options for patients with advanced
DS and tAML are few, and currently the only mo-
igure 3. Relapse-free survival (RFS). A, RFS according to receipt
f IC versus no IC. B, RFS for patients with tAML. C, RFS for
atients with RAEB/RAEB-T. The FAB classiﬁcation was deter-
ined before administration of IC.ality with curative potential is HCT. One strategy a
B&MTimed at reducing the incidence of posttransplantation
elapse has been the administration of IC before trans-
lantation. However, so far, no controlled study has
een conducted.
Yakoub-Agha et al. [31] reported substantial im-
rovement in posttransplantation RFS in patients with
econdary MDS who achieved complete remissions
ith IC compared with patients who did not respond
similar to the present results), but that study provided
o information on patients who had not received IC.
n an earlier retrospective analysis at our Center,
nderson et al. [32] compared transplant results in 20
atients who had responded to pretransplantation IC
ith results among 46 previously untreated patients,
ll with a diagnosis of secondary AML. No beneﬁt was
ssociated with IC with regard to posttransplantation
urvival.
Contrary to the report by Anderson et al. [32], this
eview included only patients with a diagnosis of MDS
r AML with multilineage dysplasia secondary to a
receding diagnosis of MDS, and the median age was
0 years older in this study. Anderson’s analysis in-
luded patients with secondary AML with or without
ultilineage dysplasia regardless of a preceding diag-
osis of MDS, which most likely accounts for their
ounger median age. Our current understanding of
DS clearly distinguishes between patients who have
econdary AML from prior chemotherapy exposure
nd patients who have tAML with multilineage dys-
lasia from a preceding diagnosis of MDS. However,
ven though the study populations were different, the
onclusions are similar, and neither study provides
onvincing evidence for a beneﬁt of pretransplanta-
ion IC. Nevertheless, the incidence of posttransplan-
ation relapse was highly dependent on the response
o IC and the severity of ﬂow scores. Patients who did
ot respond to IC and patients who relapsed before
ransplantation (after receiving IC) showed higher
ates of relapse after transplantation than did patients
ot given IC. Conceivably, as with similar observa-
ions in other disorders, pretransplantation cytotoxic
herapy was simply selected for chemotherapy-sensi-
ive or good-risk MDS patients, who subsequently had
superior outcome after transplantation. Such a no-
ion is also supported by the observation that patients
ho had no response to IC had a worse posttransplan-
ation outcome than patients who never received IC.
The median interval between the start of IC and
ransplantation was 2 months, with a range of 1 to 6
onths. Three patients who had received IC more
han 6 months before transplantation were excluded
rom this analysis because the time points were con-
idered to be too remote for IC to have an effect on
osttransplantation toxicity. The time delay from IC
o transplantation was dependent on several factors,
ncluding time to hematopoietic recovery, infections
nd overall clinical condition after IC, and time re-
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7uired to identify a suitable donor. In this retrospec-
ive review, clearly patients who underwent transplan-
ation after IC-induced remission had a superior
rognosis compared with patients who did not achieve
emission or relapsed before transplantation.
Overall, RFS among patients who had received IC
as similar to that in patients who had not received
C. Methods to further characterize biologically dis-
inct subgroups of MDS may be useful to identify
arameters that predict response to IC or posttrans-
lantation relapse; it is in these patients that one
ould anticipate the greatest beneﬁt from pretrans-
lantation IC. Our observations on ﬂow cytometric
bnormalities are of interest in this context. The num-
er of patients in whom marrow cells were analyzed
efore and after IC was too small to draw conclusions.
owever, the severity of ﬂow cytometric aberrancies
f marrow cells assessed before transplantation
howed a signiﬁcant correlation with posttransplanta-
ion relapse. Conceivably, this method can be used in
uture studies to select high-risk patients who may
eneﬁt from additional pretransplantation therapy.
These results must be interpreted with caution,
owever, because the numbers of patients in the var-
ous subgroups were small, and the trials were not
esigned to speciﬁcally address the value of IC. We do
ot know, for example, how many patients were pre-
luded from transplantation because of acute toxicities
ssociated with IC, because only patients who survived
ere referred for transplantation. There is also a po-
ential bias to select patients with what is perceived as
ore aggressive disease for IC. Furthermore, only 8
atients with a diagnosis of tAML did not receive IC,
ll of whom died of relapsed disease. It is possible that
f there had been more patients in this subgroup, a
tatistical difference would have been demonstrated
hen comparing those patients with tAML patients
ho did receive IC. In any event, among the patients
nalyzed here who came to transplantation, no signif-
cant difference in posttransplantation outcome was
ssociated with prior IC—for those with either
AEB/RAEB-T or tAML. These results, therefore,
lthough unable to answer the question of the overall
eneﬁt of IC in the treatment of advanced MDS, do
ot show an advantage of pretransplantation therapy.
CKNOWLEDGMENTS
We thank Bonnie Larson and Helen Crawford for
anuscript preparation and Joanne Greene and Eliz-
beth Soll for maintaining the patient database. Sup-
orted in part by grant nos. HL 36444, CA18029,
A15704, and CA87948 from the National Institutes
f Health (Bethesda, MD). 1
2EFERENCES
1. Deeg HJ, Appelbaum FR. Hemopoietic stem cell transplanta-
tion for myelodysplastic syndrome [review]. Curr Opin Oncol.
2000;12:116-120.
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the
classiﬁcation of the myelodysplastic syndromes. Br J Haematol.
1982;51:189-199.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised
criteria for the classiﬁcation of acute myeloid leukemia. A re-
port of the French-American-British Cooperative Group. Ann
Intern Med. 1985;103:620-625.
4. World Health Organization Classiﬁcation of Tumours. Pathology &
Genetics: Tumours of Hematopoietic and Lymphoid Tissues. Wash-
ington, DC: IARC Press; 2001.
5. Sierra J, Pérez WS, Rozman C, et al. Bone marrow transplan-
tation from HLA-identical siblings as treatment for myelodys-
plasia. Blood. 2002;100:1997-2004.
6. Runde V, de Witte T, Arnold R, et al. Bone marrow transplan-
tation from HLA-identical siblings as ﬁrst-line treatment in
patients with myelodysplastic syndromes: early transplantation
is associated with improved outcome. Chronic Leukemia
Working Party of the European Group for Blood and Marrow
Transplantation. Bone Marrow Transplant. 1998;21:255-261.
7. Greenberg P, Cox C, LeBeau MM, et al. International scoring
system for evaluating prognosis in myelodysplastic syndromes
[published erratum appears in Blood 1998;91:1100]. Blood.
1997;89:2079-2088.
8. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with tar-
geted busulfan and cyclophosphamide for hemopoietic stem
cell transplantation from related and unrelated donors in pa-
tients with myelodysplastic syndrome. Blood. 2002;100:1201-
1207.
9. de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy
followed by allogeneic or autologous stem cell transplantation
for patients with myelodysplastic syndromes (MDSs) and acute
myeloid leukemia following MDS. Blood. 2001;98:2326-2331.
0. de Witte T, Suciu S, Peetermans M, et al. Intensive chemo-
therapy for poor prognosis myelodysplasia (MDS) and second-
ary acute myeloid leukemia (sAML) following MDS of more
than 6 months duration. A pilot study by the Leukemia Coop-
erative Group of the European Organisation for Research and
Treatment in Cancer (EORTC-LCG). Leukemia. 1995;9:1805-
1811.
1. Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell
transplantation for advanced myelodysplastic syndrome after
conditioning with busulfan and fractionated total body irradi-
ation is associated with low relapse rate but considerable non-
relapse mortality. Biol Blood Marrow Transplant. 2002;8:161-
169.
2. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplanta-
tion for chronic myeloid leukemia: the inﬂuence of plasma
busulfan levels on the outcome of transplantation. Blood. 1997;
89:3055-3060.
3. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and
toxicity following bone marrow transplantation in relation to
busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:
31-42.
4. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in
hematopoietic stem cell transplantation. Ther Drug Monit.
1998;20:543-549.5. Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and
11
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
Chemotherapy and Posttransplantation Relapse in MDS
Bsyngeneic marrow transplantation for myelodysplastic
syndrome in patients 55 to 66 years of age. Blood.
2000;95:1188-1194.
6. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocom-
patibility-complex class I alleles and antigens in hematopoietic-
cell transplantation. N Engl J Med. 2001;345:1794-1800.
7. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cy-
closporine compared with cyclosporine alone for prophylaxis of
acute graft versus host disease after marrow transplantation for
leukemia. N Engl J Med. 1986;314:729-735.
8. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin)
for the treatment of steroid-refractory acute graft-versus-host
disease. Transplantation. 2001;72:1924-1929.
9. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized
non-FcR-binding anti-CD3 antibody, visilizumab, for treat-
ment of steroid-refractory acute graft-versus-host disease.
Blood. 2002;99:2712-2719.
0. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus
conference on acute GVHD grading. Bone Marrow Transplant.
1995;15:825-828.
1. Wells DA, Benesch M, Loken MR, et al. Myeloid and mono-
cytic dyspoiesis as determined by ﬂow cytometric scoring in
myelodysplastic syndrome correlates with the IPSS and with
outcome after hemopoietic stem cell transplantation. Blood.
2003;102:394-403.
2. Sievers EL, Lange BJ, Buckley JD, et al. Prediction of relapse
of pediatric acute myeloid leukemia by use of multidimensional
ﬂow cytometry. J Natl Cancer Inst. 1996;88:1483-1488.
3. Bryant E, Martin PJ. Documentation of engraftment and char-
acterization of chimerism following hematopoietic cell trans-
plantation. In: Blume KG, Forman SJ, Appelbaum FR, eds.
Thomas’ Hematopoietic Cell Transplantation. Oxford, UK: Black-
well Publishing Ltd.; 2004:234-243.
4. Scharf SJ, Smith AG, Hansen JA, McFarland C, Erlich HA.
Quantitative determination of bone marrow transplant engraft-
B&MTment using ﬂuorescent polymerase chain reaction primers for
human identity markers. Blood. 1995;85:1954-1963.
5. Petersdorf EW, Longton GM, Anasetti C, et al. Marrow trans-
plantation from unrelated donors: the signiﬁcance of HLA-
DRB1 matching on clinical outcome after HLA-A, B, DR
identical unrelated donor marrow transplantation. In: Spivak
JL, Blume KG, Bell WR, Ness MPM, Quesenberry PJ,
Wiernik PH, eds. Year Book of Hematology, 1997. St. Louis:
Mosby; 1997:349-351.
6. Slavin MA, Osborne B, Adams R, et al. Efﬁcacy and safety of
ﬂuconazole for fungal infections after marrow transplant—a
prospective, randomized, double-blind study. J Infect Dis. 1995;
171:1545-1552.
7. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G,
Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus
disease after allogeneic marrow transplant. Ann Intern Med.
1993;118:173-178.
8. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis
of cytomegalovirus infection and disease in allogeneic bone
marrow transplant recipients. Ann Intern Med. 1993;118:179-
184.
9. Boeckh M, Stevens-Ayers T, Bowden RA. Cytomegalovirus
pp65 antigenemia after autologous marrow and peripheral
blood stem cell transplantation. J Infect Dis. 1996;174:907-912.
0. Kaplan EL, Meier P. Nonparametric estimation from incom-
plete observations. J Am Stat Assoc. 1958;53:457-481.
1. Yakoub-Agha I, de La Salmonière P, Ribaud P, et al. Allogeneic
bone marrow transplantation for therapy-related myelodysplas-
tic syndrome and acute myeloid leukemia: a long-term study of
70 patients—report of the French society of bone marrow
transplantation. J Clin Oncol. 2000;18:963-971.
2. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplan-
tation for secondary acute myeloid leukemia: evaluation of
transplantation as initial therapy or following induction chemo-
therapy. Blood. 1997;89:2578-2585.
73
